Healthtech Venture Funding Southeast Asia Rebounds, but Only for High-conviction Winners

Within that deeptech lens, health tech is clearly where activity clusters. In 2025, health tech and green tech were the most active deep tech verticals in Southeast Asia, with 21 deals each, according to DealStreetAsia. The same report shows where investors become most selective: in 2025, 94.5% of the region’s deeptech deals were early-stage, while the funnel tightened at later rounds. Series A activity fell from 29 deals in 2024 to 17 in 2025, and only four Series B rounds were recorded across the region. The implication for healthtech founders is simple: technical novelty can open doors, but follow-on capital increasingly depends on evidence of demand, unit economics, and a credible path to scale.

Selective Capital, Clearer Proof: What Investors Are Buying Now

Investor selectivity also shows up when you zoom out to Asia-Pacific digital health capital flows. Galen Growth reports that Asia-Pacific healthtech startups raised about $2 billion across 244 deals in 2024, then recovered 14% to roughly $2.4 billion in 2025. But in Q1 2026, Galen Growth highlights a bifurcation: $2.65B in strategic capital versus $244M in VC, based on 216 venture funding transactions (excluding M&A and IPO exits) and 676 corporate partnerships recorded between 1 January and 31 March 2026. As a comparison point, New Market Pitch’s global equity-round analysis (July 2025 to June 2026) shows Asia-Pacific produced 3 deals and $235.2M, or 11.4% of capital, noting this signal is heavily shaped by PB Health and reflects strategic platform formation more than a diversified venture base.

For Southeast Asia specifically, Tracxn’s view of the healthtech startup landscape provides added context on how concentrated outcomes can be. Tracxn lists 3,696 HealthTech companies in Southeast Asia, with 458 having secured funding; 112 have reached Series A or higher, and 66 to Series B or beyond. Tracxn also notes the HealthTech sector in Southeast Asia saw total funding of more than $1.5B over the last 10 years, with the most funding in 2023 at more than $400M, and total funding of $35.7M in 2026 year to date. Company snapshots underline the mix of maturity and selective progression: Docquity (Singapore) is listed at Series C with $57.5M total funding, while Naluri (Kuala Lumpur) is listed at Series B with $19.9M total funding and a latest round dated Aug 12, 2025.

The practical takeaway is that the “rebound” is real, but it is conditional. DealStreetAsia’s deeptech framing argues investors are concentrating funding in higher-conviction companies with clearer technical moats, stronger IP defensibility, proven commercial demand, and more visible paths to category leadership. For healthtech teams, that raises the bar from technical proof to commercial proof to scale proof, especially as the later-stage funnel remains thin. For operators, it also means aligning the business with the kinds of infrastructure-led partnerships and strategic capital flows that Galen Growth shows are now a major part of Asia-Pacific digital health financing, alongside a smaller pool of pure venture dollars.